Bio-Techne (TECH) Stock Could Be 26% Overvalued On Growth Hopes

Bio-Techne’s share price has recovered over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the stock trading at a premium rather than offering clear value. Bio-Techne has declined about 40.3% over the past 5 years, which raises the question of whether the recent rebound has run ahead of the underlying fundamentals. Expectations for future revenue and cash flow growth can support a premium valuation for Bio-Techne,…Read More